Author: aesteras

Creating new opportunities for collaboration – pharma speed dating

On 30th January 2015, the breakout space at the Wolfson Education Centre at Imperial’s Hammersmith campus was buzzing with more than 100 dates between 40 Imperial academics from different faculties, and representatives from 7 major Pharma companies.

The first Pharma speed dating @ ICL event was part of the launch program for the Imperial Confidence in Concept funding scheme, and was organized by the Corporate Partnerships team. Jonathan Weber, Vice-Dean of Research and Imperial College AHSC Director said

“The Pharma speed dating event fits with our strategy to strengthen Imperial relationship with the Pharmaceutical industry and to provide young PIs an opportunity to have their first industrial interactions”.

Academics had only 20 minutes to pitch their ideas to company representatives and discuss common interest for collaborations.

Both academics and company representatives enjoyed a day of interesting and open scientific discussions.

Silvia Santos, a starting group leader at the Imperial MRC-Clinical Science Centre said:

It was very informative to understand what a therapeutic target is to Pharma companies and the path to get into having a potential interesting target. But perhaps even more exciting was realising how complementary our approaches in the lab are with some of the companies and start discussions for potential collaborations.”

Following on from the event, the Corporate Partnerships team is busy following up with several companies who have opened opportunities for collaboration with the College.

The Corporate Partnerships team is expecting to run this event again next year. If your company is interested in participating in the next speed dating @ ICL event, please get in touch with us at enterprise-fom@imperial.ac.uk.

First ICL-Pharma Speed Dating event creates new opportunities for collaboration

Lynne Murray
Entrepreneur in Residence, Dr Lynne Murray

On 30 of January,the breakout space at the Wolfson education centre was buzzing with more than 100 dates between 40 Imperial academics from different faculties, and representatives from AstraZeneca, GSK, Lillly, MedImmune, Pfizer, Sanofi and UCB pharma. As a result, follow-up conversations are ongoing, and GSK and Sanofi are coming back to Imperial to search for collaborations.

The first ICL-Pharma Speed Dating event was part of the launching program of the Imperial Confidence in Concept funding scheme, and was organized by the Corporate Partnerships team.  Jonathan Weber, Vice Dean (Research) said “The Pharma speed dating event fits with our strategy to strengthen Imperial relationship with the Pharmaceutical industry and to provide young PIs an opportunity to have their first industrial interactions”. Academics had only 20 minutes to pitch their ideas to company representatives and discuss common interest for collaborations. The event was also the launch of the new Entrepreneur in Residence (EiR), Dr Lynne Murray. “During my tenure as the EiR at Imperial, I will act as an advisor, mentor and trouble-shooter for translational and commercial research directions. I did my PhD at Imperial and I am absolutely thrilled to spend time with Imperial academics” said Lynne. Currently employed by Medimmune, Lynne will act as a confidential and independent advisor with more than 15 years R&D and BD experience in the pharmaceutical and biotechnology industry to provide advice on translational research collaborations with industry.

Both academics and company representatives enjoyed a day of interesting and open scientific discussions. Silvia Santos, a starting group leader at the MRC-Clinical Science Centre said “ It was very informative to understand what a therapeutic target is to pharma companies and the path to get into having a potential interesting target. But perhaps even more exciting was realising how complementary our approaches in the lab are with some of the companies and start discussions for potential collaborations”.

As a result of the event, the Corporate Partnerships team is busy setting second dates, and several companies have opened opportunities for collaboration with Imperial College. Genzyme opened a call for projects in inherited rare diseases that will be followed by a visit of their research team to discuss with short-listed candidates. GSK gave a presentation on their Discovery partnerships with Academia and Fast Track challenges, on 23 March at the Wolfson education centre on the Hammersmith campus.

All these calls are advertised through different channels including Faculty mailing lists, and research managers.

If you have any questions about these initiatives or you would like to discuss potential industrial collaborations, please get in touch with the Corporate Partnerships team at enterprise-fom@imperial.ac.uk.

 

Dr Alexandra Esteras-Chopo
Corporate Partnerships Associate
Faculty of Medicine